ethyl-(1-phenyl-propyl)-ether | 62163-19-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-(1-phenyl-propyl)-ether
• 英文别名: Aethyl-(1-phenyl-propyl)-aether；(+/-)-1-Aethoxy-1-phenyl-propan；(α-Aethoxy-propyl)-benzol；Aethyl-(α-phenyl-propyl)-aether；1-phenyl-1-ethoxy-propane；(1-Ethoxypropyl)benzene；1-ethoxypropylbenzene
• CAS: 62163-19-3
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: WTXZCYKFEJKRAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-苯丙醇 在 sodium 、 xylene 作用下， 生成 ethyl-(1-phenyl-propyl)-ether
  参考文献：
  名称：

  Meisenheimer; Link, Justus Liebigs Annalen der Chemie, 1930, vol. 479, p. 211,248

  摘要：

  DOI：

文献信息

• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• Carbene in Rigid Matrix. XI. Temperature and Matrix Effect on Phenylcarbene Processes in Ether and Amine
  作者：Hideo Tomioka、Shinji Suzuki、Yasuji Izawa

  DOI：10.1246/bcsj.55.492

  日期：1982.2

  Product distributions from reactions of phenylcarbene with diethyl or diisopropyl ether or diethylamine were found to be highly dependent on reaction temperature. As temperature decreases, the C–O displacement reaction and N–H insertion are decreased. Concomitantly, primary C–H insertion products markedly increase especially at lower matrix temperatures.

  苯卡宾与二乙醚或二异丙醚或二乙胺反应的产物分布被发现高度依赖于反应温度。随着温度降低，C-O 置换反应和 N-H 插入减少。同时，初级 C-H 插入产物显着增加，尤其是在较低的基质温度下。
• Substituted aralkyl derivatives
  申请人：Lohray B. Braj

  公开号：US20060142277A1

  公开（公告）日：2006-06-29

  The present invention relates to novel substituted aralkyl derivatives of the general formula (I) and (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一种新的通式（I）和（IIIa）的取代芳基烷基衍生物，它们的衍生物，类似物，互变异构体，药学上可接受的盐，药学上可接受的溶剂化合物，包含它们的制药组合物，以及这些化合物在医学上的应用和其制备中所涉及的中间体。
• Halogen-containing resin lens material
  申请人：KUREHA KAGAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0142921A1

  公开（公告）日：1985-05-29

  A halogen-containing resin lens material, having a refractive index of no = 1.55 or higher, an Abbe number of 27 or higher and good dyeable property and comprising a copolymer containing 10 to 90 wt. % of a monomer (I) represented by the formula (I) shown below: wherein: R1 represents hydrogen or CH3 group; X' a halogen atom except for fluorin; and p the number of substituted halogens which is an integer selected from 1 to 5, and n is an integer selected from 1 to 4, R1 existing in plural number and being either identical or different, X1 when existing in plural number being either identical or different and 10 to 70 wt. % of a crosslinking monomer having two or more polymerizable functional groups (the percentages being based on the copolymer weight).

  一种含卤素树脂镜片材料，其折射率为 no = 1.55 或更高，阿贝数为 27 或更高，并具有良好的可染性，其包含一种共聚物，该共聚物含有 10 至 90 wt.%由下式（I）表示的单体（I）：其中：R1 代表氢或 CH3 基团；X'为除氟以外的卤素原子；p 为取代卤素的数目，为 1 至 5 的整数，n 为 1 至 4 的整数，R1 为复数且相同或不同，X1 为复数时相同或不同，以及 10 至 70 wt.%具有两个或更多可聚合官能团的交联单体（百分比基于共聚物重量）。
• Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0268878A2

  公开（公告）日：1988-06-01

  Disclosed herein are salicylic acid copolymers having a weight average molecular weight of 500 10,000 and obtained (a) by condensing salicylic acid (i) with a benzyl alcohol (ii) and/or benzyl ether (iii) or a benzyl halide (iv) in the presence of an acid catalyst or (b) by reacting a co-condensation resin of (i) and (ii) and/or (iii) with (iv) or (c) by reacting a co-condensation resin of (i) and (ii) and/or (iii) or (iv) with a styrene derivative in the presence of an acid catalyst; multivalent metal salts of the salicylic acid copolymers; color-developing agents comprising the multivalent metal salts; and color-developing sheets suited for pressure-sensitive copying paper and comprising the color-developing agents. Their production processes are also disclosed.

  本文公开了水杨酸共聚物，其重量平均分子量为 500 10、000 的水杨酸共聚物；(a)在酸催化剂存在下，将水杨酸(i)与苄醇(ii)和/或苄醚(iii)或苄基卤化物(iv)缩合而得，或(b)将(i)和(ii)和/或(iii)的共缩合树脂与(iv)反应而得，或(c)在酸催化剂存在下，将(i)和(ii)和/或(iii)或(iv)的共缩合树脂与苯乙烯衍生物反应而得；水杨酸共聚物的多价金属盐；由多价金属盐组成的显色剂；以及由显色剂组成的适用于压敏复印纸的显色薄片。此外，还公开了它们的生产工艺。